Evidence map›Paper›PMID 42734728›Full record

ArticleHuman cell2026

Mechanistic study of IL-17 inhibitors in alleviating inflammation in ankylosing spondylitis by regulating Treg cell function through modulation of the Ahr signaling pathway.

Chao Sun, Bihong Quan, Zhiyuan Feng, Jie Zhou, Xinmeng Yang, Dengxiao Hong, Changhao Xie, Xin Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao Sun *Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Bihong Quan *School of Medical Imaging, Bengbu Medical University, Bengbu, 233004, China.
Zhiyuan FengDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Jie ZhouDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Xinmeng YangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Dengxiao HongDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Changhao XieDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China.
Xin WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, China. fsmyk202307@163.com.

Funding

the Anhui Province Key Laboratory of Immunology in Chronic Diseases No. KLICD-2023-D3the Anhui Provincial Key Research and Development Project No. 202304295107020088the Natural Science Research Project of Anhui Educational Committee No. 2024AH051246
6 · The paper itself

Abstract

This study explored whether Interleukin-17 (IL-17) inhibitors alleviate inflammation in ankylosing spondylitis (AS) by modulating the aryl hydrocarbon receptor (Ahr) signaling pathway to influence regulatory T cell (Treg) function. A proteoglycan (PG)-induced mouse model of AS, comprising a control group, a model group (PG), and an IL-17 inhibitor treatment group (PG + Secukinumab), was established. Arthritis severity was assessed using arthritis scoring, histopathological analysis, molecular biology techniques, and flow cytometry to evaluate inflammation, expression of inflammatory factors, Ahr signaling pathway activity, and the proportion of Tregs. An Ahr inhibitor (CH-223191) was used in combination with secukinumab to validate the mechanism. The results showed that the IL-17 inhibitor significantly reduced arthritis inflammation in AS mice, downregulating the expression of pro-inflammatory factors such as IL-17, IL-6, and TNF-α. Moreover, it activated the Ahr signaling pathway while increasing the proportion of Tregs and the expression of their functional anti-inflammatory factors IL-10 and TGF-β. Administration of the Ahr inhibitor reversed the protective effects of the IL-17 inhibitor. In conclusion, the IL-17 inhibitor alleviated AS inflammation by activating the Ahr signaling pathway and enhancing Treg cell function, thus correcting immune imbalance. This study reveals a novel "IL-17 inhibitor-Ahr-Treg" immune regulatory axis, providing novel insights into immunotherapy for AS.

Indexed as

Antibodies, Monoclonal, HumanizedInflammationInterleukin-17Receptors, Aryl HydrocarbonSignal TransductionSpondylitis, AnkylosingT-Lymphocytes, RegulatoryAnimalsDisease Models, AnimalHumansInflammation MediatorsMicePyrazolesAntibodies, Monoclonal, HumanizedInflammation MediatorsInterleukin-17PyrazolesReceptors, Aryl HydrocarbonsecukinumabAnkylosing spondylitisAryl hydrocarbon receptorIL-17 inhibitorInflammatory signaling pathwayRegulatory T cells

Identifiers

PMID42734728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.